Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: A case control study

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Primary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure and death. High dose chemotherapy with peripheral blood stem cell transplant (PBSCT) has been associated with higher response rates and seemingly higher overall survival than standard chemotherapy. Selection bias, however, confounds interpretation of these results. We performed a case match control study comparing overall survival of 63 transplanted AL patients to 63 non-transplanted patients. Matching criteria included age, gender, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24 hour urine protein, and serum alkaline phosphatase. According to design, there was no difference between the groups with respect to gender (57% males), age (median 53 years), left ventricular ejection fraction (65%), number of patients with peripheral nerve involvement (17%), cardiac interventricular septal wall thickness (12 mm), serum creatinine (1.1 mg/dL), and bone marrow plasmacytosis (8%). Sixty-six patients have died (16 cases and 50 controls). For PBSCT and control groups respectively, the 1, 2, and 4 year overall survival rates are: 89 and 71%; 81 and 55%; and 71 and 41%. Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL. Supported in part by CA 62242(R.A.K), CA 91561(A.D) from the National Cancer Institute, and the Robert A. Kyle Hematology Malignancies Fund, Mayo Foundation.

Original languageEnglish (US)
Title of host publicationAmyloid and Amyloidosis
PublisherCRC Press
Pages121-123
Number of pages3
ISBN (Electronic)9781420037494
ISBN (Print)0849335345, 9780849335341
StatePublished - Jan 1 2004

Fingerprint

Case-Control Studies
Transplants
Survival
Amyloidosis
Stroke Volume
Creatinine
Drug Therapy
Paraproteinemias
National Cancer Institute (U.S.)
Selection Bias
Hematology
Serum
Peripheral Nerves
Alkaline Phosphatase
Blood Proteins
Survival Rate
Randomized Controlled Trials
Bone Marrow
Peripheral Blood Stem Cells
Primary amyloidosis

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)

Cite this

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant : A case control study. / Dispenzieri, Angela; Kyle, R. A.; Lacy, Martha; Therneau, Terry M; Gertz, Morie.

Amyloid and Amyloidosis. CRC Press, 2004. p. 121-123.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{429b741e39254a4c86f590573347c2c2,
title = "Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: A case control study",
abstract = "Primary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure and death. High dose chemotherapy with peripheral blood stem cell transplant (PBSCT) has been associated with higher response rates and seemingly higher overall survival than standard chemotherapy. Selection bias, however, confounds interpretation of these results. We performed a case match control study comparing overall survival of 63 transplanted AL patients to 63 non-transplanted patients. Matching criteria included age, gender, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24 hour urine protein, and serum alkaline phosphatase. According to design, there was no difference between the groups with respect to gender (57{\%} males), age (median 53 years), left ventricular ejection fraction (65{\%}), number of patients with peripheral nerve involvement (17{\%}), cardiac interventricular septal wall thickness (12 mm), serum creatinine (1.1 mg/dL), and bone marrow plasmacytosis (8{\%}). Sixty-six patients have died (16 cases and 50 controls). For PBSCT and control groups respectively, the 1, 2, and 4 year overall survival rates are: 89 and 71{\%}; 81 and 55{\%}; and 71 and 41{\%}. Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL. Supported in part by CA 62242(R.A.K), CA 91561(A.D) from the National Cancer Institute, and the Robert A. Kyle Hematology Malignancies Fund, Mayo Foundation.",
author = "Angela Dispenzieri and Kyle, {R. A.} and Martha Lacy and Therneau, {Terry M} and Morie Gertz",
year = "2004",
month = "1",
day = "1",
language = "English (US)",
isbn = "0849335345",
pages = "121--123",
booktitle = "Amyloid and Amyloidosis",
publisher = "CRC Press",

}

TY - CHAP

T1 - Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant

T2 - A case control study

AU - Dispenzieri, Angela

AU - Kyle, R. A.

AU - Lacy, Martha

AU - Therneau, Terry M

AU - Gertz, Morie

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Primary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure and death. High dose chemotherapy with peripheral blood stem cell transplant (PBSCT) has been associated with higher response rates and seemingly higher overall survival than standard chemotherapy. Selection bias, however, confounds interpretation of these results. We performed a case match control study comparing overall survival of 63 transplanted AL patients to 63 non-transplanted patients. Matching criteria included age, gender, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24 hour urine protein, and serum alkaline phosphatase. According to design, there was no difference between the groups with respect to gender (57% males), age (median 53 years), left ventricular ejection fraction (65%), number of patients with peripheral nerve involvement (17%), cardiac interventricular septal wall thickness (12 mm), serum creatinine (1.1 mg/dL), and bone marrow plasmacytosis (8%). Sixty-six patients have died (16 cases and 50 controls). For PBSCT and control groups respectively, the 1, 2, and 4 year overall survival rates are: 89 and 71%; 81 and 55%; and 71 and 41%. Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL. Supported in part by CA 62242(R.A.K), CA 91561(A.D) from the National Cancer Institute, and the Robert A. Kyle Hematology Malignancies Fund, Mayo Foundation.

AB - Primary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure and death. High dose chemotherapy with peripheral blood stem cell transplant (PBSCT) has been associated with higher response rates and seemingly higher overall survival than standard chemotherapy. Selection bias, however, confounds interpretation of these results. We performed a case match control study comparing overall survival of 63 transplanted AL patients to 63 non-transplanted patients. Matching criteria included age, gender, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24 hour urine protein, and serum alkaline phosphatase. According to design, there was no difference between the groups with respect to gender (57% males), age (median 53 years), left ventricular ejection fraction (65%), number of patients with peripheral nerve involvement (17%), cardiac interventricular septal wall thickness (12 mm), serum creatinine (1.1 mg/dL), and bone marrow plasmacytosis (8%). Sixty-six patients have died (16 cases and 50 controls). For PBSCT and control groups respectively, the 1, 2, and 4 year overall survival rates are: 89 and 71%; 81 and 55%; and 71 and 41%. Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL. Supported in part by CA 62242(R.A.K), CA 91561(A.D) from the National Cancer Institute, and the Robert A. Kyle Hematology Malignancies Fund, Mayo Foundation.

UR - http://www.scopus.com/inward/record.url?scp=85057671851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057671851&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85057671851

SN - 0849335345

SN - 9780849335341

SP - 121

EP - 123

BT - Amyloid and Amyloidosis

PB - CRC Press

ER -